- Report
- February 2018
- 77 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- March 2021
- 168 Pages
Global
From €5928EUR$6,168USD£5,084GBP
- Report
- September 2019
Global
From €5161EUR$5,370USD£4,426GBP
- Report
- May 2023
- 160 Pages
Global
From €5766EUR$5,999USD£4,945GBP
Novorapid is a brand of insulin analogs used to treat endocrine and metabolic disorders. It is a fast-acting insulin that is used to control blood sugar levels in people with diabetes. Novorapid is a recombinant human insulin analog that is produced by recombinant DNA technology. It is designed to act faster and more predictably than regular human insulin. It is used to treat both type 1 and type 2 diabetes. Novorapid is administered subcutaneously and is usually taken before meals. It is used to control postprandial glucose levels and to prevent long-term complications of diabetes.
The Novorapid market is highly competitive, with several companies offering insulin analogs. These include Novo Nordisk, Eli Lilly, Sanofi, Merck, and Boehringer Ingelheim. Each company offers a range of insulin analogs, including Novorapid, to meet the needs of people with diabetes. Show Less Read more